These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6645804)

  • 1. Molindone: higher doses needed to block pergolide-induced elevation of serum corticosterone than to elevate dopamine metabolites in brain.
    Fuller RW; Snoddy HD
    Life Sci; 1983 Dec; 33(23):2357-61. PubMed ID: 6645804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats. Characterization by the use of antagonists.
    Fuller RW; Snoddy HD
    Neuropharmacology; 1984 Dec; 23(12A):1389-94. PubMed ID: 6527743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated administration of pergolide to rats attenuates the acute elevation of serum corticosterone by pergolide.
    Fuller RW; Snoddy HD
    Pharmacol Biochem Behav; 1981 Dec; 15(6):933-6. PubMed ID: 7323119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW; Clemens JA; Hynes MD
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of serum corticosterone in rats by dopamine agonists related in structure to pergolide.
    Fuller RW; Snoddy HD; Mason NR; Clemens JA; Bemis KG
    Neuroendocrinology; 1983; 36(4):285-90. PubMed ID: 6866215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential dose- and time-dependent effects of molindone on dopamine neurons of rat brain: mediation by irreversible inhibition of monoamine oxidase.
    Meller E; Friedman E
    J Pharmacol Exp Ther; 1982 Mar; 220(3):609-15. PubMed ID: 6121048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine and neurochemical effects of (+)-PHNO, a dopamine D2 agonist.
    Gust CM; Hemrick-Luecke SK; Fuller RW
    J Neural Transm; 1989; 75(1):11-20. PubMed ID: 2563751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and behavioral evaluation of pergolide as a dopamine agonist in the rat brain.
    Jiang DH; Reches A; Wagner HR; Fahn S
    Neuropharmacology; 1984 Mar; 23(3):295-301. PubMed ID: 6539428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pergolide elevation of MHPG sulphate concentration in rat hypothalamus blocked by spiperone and mimicked by other dopamine agonists.
    Fuller RW; Hemrick-Luecke SK; Perry KW; Toomey RE
    J Pharm Pharmacol; 1985 Apr; 37(4):268-70. PubMed ID: 2860228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of molindone and fluphenazine on the brain concentration of some phenolic and catecholic amines in the mouse and the rat.
    Juorio AV
    Br J Pharmacol; 1980 Nov; 70(3):475-80. PubMed ID: 6777007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats.
    Meller E
    Psychopharmacology (Berl); 1982; 76(3):222-7. PubMed ID: 6808540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine receptor affinities in vitro and neurochemical effects in vivo of pergolide and its metabolites.
    Wong DT; Threlkeld PG; Bymaster FP
    Arzneimittelforschung; 1993 Apr; 43(4):409-12. PubMed ID: 7684223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term decreases in striatal dopamine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid after a single injection of amphetamine in iprindole-treated rats: time course and time-dependent interactions with amfonelic acid.
    Steranka LR
    Brain Res; 1982 Feb; 234(1):123-36. PubMed ID: 7059818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain.
    Asanuma M; Ogawa N; Nishibayashi S; Kawai M; Kondo Y; Iwata E
    Arch Int Pharmacodyn Ther; 1995; 329(2):221-30. PubMed ID: 8540762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological significance of dopamine autoreceptors as studied following their selective blockade by molindone.
    Alander T; Grabowska-Andén M; Andén NE
    J Pharm Pharmacol; 1980 Nov; 32(11):780-2. PubMed ID: 6110728
    [No Abstract]   [Full Text] [Related]  

  • 16. Preclinical studies on quinelorane, a potent and highly selective D2-dopaminergic agonist.
    Foreman MM; Fuller RW; Hynes MD; Gidda JS; Nichols CL; Schaus JM; Kornfeld EC; Clemens JA
    J Pharmacol Exp Ther; 1989 Jul; 250(1):227-35. PubMed ID: 2526214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of amantadine and amfonelic acid on dopamine metabolism in rat brain.
    Fuller RW; Snoddy HD; Perry KW
    Brain Res Bull; 1981 Feb; 6(2):141-3. PubMed ID: 7470959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat.
    McMillen BA; McDonald CC
    Neuropharmacology; 1983 Mar; 22(3):273-8. PubMed ID: 6133232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced stereotyped response to amphetamine after pretreatment with small doses of molindone.
    Conway P; Uretsky NJ
    Neuropharmacology; 1983 May; 22(5):579-86. PubMed ID: 6308493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity.
    Feenstra MG; Sumners C; Goedemoed JH; de Vries JB; Rollema H; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(2):108-15. PubMed ID: 6646238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.